MedTrace Logo

Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441

NCT02479204 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-09-22

No results posted yet for this study

Summary

The aim of the study is to investigate the safety of the concomitant administration of ACT-334441 with cardiovascular drugs.

Conditions

  • Healthy Subjects

Interventions

DRUG

ACT-334441 2 mg

capsule containing ACT-334441 at a strength of 2 mg

DRUG

ACT-334441 4 mg

capsule containing ACT-334441 at a strength of 4 mg

DRUG

Placebo

ACT-33441-matching placebo

DRUG

Atenolol

film-coated tablet containing atenolol at a strength of 50 mg

DRUG

Diltiazem ER

film-coated tablet containing diltiazem at a strength of of 120 mg

Sponsors & Collaborators

  • Viatris Innovation GmbH

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Viatris Innovation GmbH

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-28
Primary Completion
2016-05-01
Completion
2016-05-01

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02479204 on ClinicalTrials.gov